New computational modeling of avian influenza variants' immunoprotein interactions—developed by a research team at the ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...

Successful high-affinity B cells can proliferate under special conditions that reduce the risk of mutation. Capturing this ...

Vimkunya™ (chikungunya vaccine, recombinant) is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years ...

Kurt Gustafson; Chief Financial Officer, Executive Vice President - Finance; OmniAb Inc. Matthew Foehr; President, Chief Executive Officer, Director; OmniAb Inc. Joe ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ETCompany ParticipantsKurt Gustafson - Chief Financial OfficerMatt ...

Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here. Lower blood eosinophil counts ...